About PanCAD.ai — NTU Technology, Taiwan Startup

Our Mission

Every CT deserves a second look

Pancreatic cancer's five-year survival is under 10%, mostly because it's found too late. We believe if AI can help radiologists see tumors while they're still small, thousands of families would have different stories.

Patient first

Every product decision starts with “does it help patients?” — not a tech demo, but a guardian of life.

Evidence first

Every claim is backed by literature and regulatory approval. Honest data is our basic respect for medical partners.

Walking with physicians

AI doesn't replace doctors; it lets them see earlier and more precisely. We stand with radiology and GI teams.

Milestones

From fundamental research to clinical care

2016

Prof. Wang (NTU) and Prof. Liao (NTUH) launch early pancreatic cancer imaging AI research

2019

NTU research team begins multi-center clinical validation

2022.11

PanCAD.ai Co., Ltd. founded; technology licensed for commercialization

2023

First Margulis Award for Taiwan at RSNA; SNQ, Taipei BioTech, National Innovation Awards

2023

FDA Breakthrough designation; TFDA license No. 007946

2026

Deployed at medical centers, regional hospitals and health centers; 2,156+ cases

Technology Origin

A decade of persistence behind a world first

PANCREASaver® grew from long-term research at NTUH and NTU — the world's first AI-assisted diagnostic device focused on early pancreatic cancer detection.

Prof. Wei-Chung Wang, NTU

Original inventor — core research team for AI pancreatic lesion detection

Prof. Wei-Chih Liao, NTUH

Clinical validation lead — prospective multi-center validation in real world

PanCAD.ai

Commercialization — taking the technology from lab to bedside

Co-founders

One writes the algorithm, one guards the clinic — so pancreatic cancer under 2 cm is never missed.

Prof. Wei-Chung Wang

Professor, Institute of Applied Mathematical Sciences, NTU | Founder & Director, MeDA Lab | Co-founder, PanCAD.ai

Ph.D. in Applied Mathematics, University of Maryland (1996). Over 25 years in medical AI and high-performance scientific computing, with 100+ publications (Nature Medicine, The Lancet Digital Health, Radiology). Rigorous mathematics that makes AI judgment trustworthy.

🔬 Smart Healthcare & Technical Innovation

Breakthrough Device Designation: led the team that developed PANCREASaver — the AI pancreatic cancer detection system — receiving FDA Breakthrough Device Designation in 2022 and the Taiwan MOHW medical device license in 2023.
Exceptional clinical precision: the system accurately predicts whether a CT scan contains pancreatic cancer and its location — 92.1% sensitivity for tumors under 2 cm, catching up to 92% of early lesions easily missed by the naked eye or radiologists.
Cross-domain industrialization: co-founded PanCAD.ai to turn laboratory research into commercially viable, clinically practical medical software — elevating Taiwan's international competitiveness in smart healthcare.

🏆 Major Awards & Honors

2025 | NSTC Outstanding Research Award
2025 | TWSIAM Fellow
2023 | RSNA Alexander R. Margulis Award for Scientific Excellence
2024 | SNQ Smart Healthcare Silver Award (PANCREASaver)
2024 | Taipei BioTech Award – Cross-domain Excellence Gold (PANCREASaver)
2021–2023 | National Innovation Award & Innovation Advancement Award (multiple wins)
2021–2022 | NSTC Future Tech Award
2023 | Y.Z. Hsu Science Paper Award – Artificial Intelligence
2010–2011 | NTU University-wide Teaching Excellence Award

📚 Academic Impact & Key Positions

100+ publications in top journals including Nature Medicine, The Lancet Digital Health, Radiology, and SIAM Journal on Matrix Analysis and Applications.
Former Convener of the NSTC Mathematics Division (2021–2023) and President of TWSIAM (2020–2022).
Currently a researcher at NTU Hospital Center for Smart Healthcare and a member of the Taiwan Radiological Society AI & Imaging Informatics Committee — bridging mathematics, informatics, and clinical medicine.

Prof. Wei-Chih Liao

Attending Physician, Gastroenterology & Hepatology, NTU Hospital | Co-founder, PanCAD.ai

Prof. Liao has achieved multiple landmark accomplishments in cross-disciplinary medical research and clinical invention.

🎖️ Major Achievements & Contributions

World-first AI pancreatic cancer detection system (PANCREASaver): co-developed with Prof. Wei-Chung Wang across medicine and AI imaging — analyzing CT scans to help physicians pinpoint early micro pancreatic tumors invisible to the naked eye. Showcasing Taiwan's leadership in smart healthcare, featured in Discovery Channel's 'Exploring Taiwan: Health Equity'.
Multiple medical and invention patents — 4 US patents and 5 Taiwan invention patents, including the 'Medical Image Analysis System and Method' behind PANCREASaver, and the 'Endoscopic Droplet & Aerosol Shield Mouthpiece' invented during the pandemic to protect healthcare workers.
113th NSTC Outstanding Research Award

🩺 Research & Clinical Expertise

Gastroenterology & endoscopic techniques: biliopancreatic endoscopy, endoscopic resection of GI tumors, endoscopic ultrasound (EUS), and GI stent placement.
Pancreatic disease care: epidemiology and clinical treatment of pancreatic cancer and pancreatitis.
Cross-disciplinary AI medical applications: bringing AI into clinical image interpretation and healthcare IT architecture.

Representative joint publications (read the originals)

健康台灣深耕計畫

不只是產品，更是對台灣的承諾

我們投入「健康台灣深耕計畫」，把 AI 早期偵測帶進更多醫療場域，並推動胰臟健康衛教——讓早期發現，從醫學中心走向每一個社區。

不僅是 AI 醫療軟體，更完美契合「深耕計畫」三大核心精神

評審委員最在乎的人工智慧指標，我們都幫您準備好了

優化醫療工作條件

計畫痛點：醫護過勞、重複性閱片工作繁重。

PanCAD 解方：作為放射科醫師的 AI 影像 Copilot，自動預篩影像，提高檢驗效率並降低死亡率。

導入智慧科技醫療

計畫痛點：許多人工智慧仍停留在論文階段，無法臨床應用。

PanCAD 解方：源自台大研究的成熟 AI 檢測產品，無縫介接醫院 PACS 系統，滿足深耕計畫技術規格。

醫療資訊架構環境優化

對接指標：社會責任與醫療永續。

PanCAD 解方：透過數位化 AI 預篩機制提升診斷韌性，早期發現胰臟癌，落實精準醫療資源分配。

Making early detection reachable.